A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

NCT06436183 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis
Atopic
Dermatitis
Dermatologic Disease
Eczema
Eczema Atopic Dermatitis
Eczema, Atopic

Interventions

DRUG: Camoteskimab
DRUG: Placebo

Sponsor

Apollo Therapeutics Ltd